about
Interim Guidelines for Pregnant Women During a Zika Virus Outbreak — United States, 2016Zika Virus Infection Among U.S. Pregnant Travelers — August 2015–February 2016Update: Interim Guidance for Health Care Providers Caring for Women of Reproductive Age with Possible Zika Virus Exposure — United States, 2016Update: Interim Guidelines for Health Care Providers Caring for Pregnant Women and Women of Reproductive Age with Possible Zika Virus Exposure — United States, 2016Zika Virus and PregnancyPossible Zika Virus Infection Among Pregnant Women - United States and Territories, May 2016Contraceptive Use Among Nonpregnant and Postpartum Women at Risk for Unintended Pregnancy, and Female High School Students, in the Context of Zika Preparedness - United States, 2011-2013 and 2015Estimating the Number of Pregnant Women Infected With Zika Virus and Expected Infants With Microcephaly Following the Zika Virus Outbreak in Puerto Rico, 2016Birth Defects Among Fetuses and Infants of US Women With Evidence of Possible Zika Virus Infection During PregnancyPreparing for biological threats: Addressing the needs of pregnant womenBaseline Prevalence of Birth Defects Associated with Congenital Zika Virus Infection — Massachusetts, North Carolina, and Atlanta, Georgia, 2013–2014Vital Signs: Update on Zika Virus–Associated Birth Defects and Evaluation of All U.S. Infants with Congenital Zika Virus Exposure — U.S. Zika Pregnancy Registry, 2016CDC Online Course: Reproductive Health in Emergency Preparedness and Response.The Centers for Disease Control and Prevention's maternal health response to 2009 H1N1 influenza.Pandemic 2009 influenza A (H1N1) in 71 critically ill pregnant women in California.A randomized clinical trial on the effects of progestin contraception in the genital tract of HIV-infected and uninfected women in Lilongwe, Malawi: Addressing evolving research priorities.Antiretroviral pharmacokinetics in mothers and breastfeeding infants from 6 to 24 weeks post-partum: results of the BAN Study.Evaluating nurses' implementation of an infant-feeding counseling protocol for HIV-infected mothers: The Ban Study in Lilongwe, MalawiSafety of tenofovir during pregnancy for the mother and fetus: a systematic review.Dietary patterns and maternal anthropometry in HIV-infected, pregnant Malawian womenReducing lost to follow-up in a large clinical trial of prevention of mother-to-child transmission of HIV: the Breastfeeding, Antiretrovirals and Nutrition study experience.Recent trends in hepatic diseases during pregnancy in the United States, 2002-2010.Contraceptive availability during an emergency response in the United States.The acceptance and feasibility of replacement feeding at 6 months as an HIV prevention method in Lilongwe, Malawi: results from the BAN studyAdherence to extended postpartum antiretrovirals is associated with decreased breast milk HIV-1 transmission.The role of co-infections in mother-to-child transmission of HIV.Hepatitis B virus infection among HIV-infected pregnant women in Malawi and transmission to infants.Stopping the control arm in response to the DSMB: mother's choice of HIV prophylaxis during breastfeeding in the BAN Study.A lipid-based nutrient supplement mitigates weight loss among HIV-infected women in a factorial randomized trial to prevent mother-to-child transmission during exclusive breastfeedingEffect of cytomegalovirus infection on breastfeeding transmission of HIV and on the health of infants born to HIV-infected mothers.Health outcomes of HIV-exposed uninfected African infantsAntiretroviral Treatment Is Associated With Iron Deficiency in HIV-Infected Malawian Women That Is Mitigated With Supplementation, but Is Not Associated With Infant Iron Deficiency During 24 Weeks of Exclusive Breastfeeding.Complications of cesarean deliveries among HIV-infected women in the United States.Thiamin and Riboflavin in Human Milk: Effects of Lipid-Based Nutrient Supplementation and Stage of Lactation on Vitamer Secretion and Contributions to Total Vitamin Content.Impact of daily cotrimoxazole on clinical malaria and asymptomatic parasitemias in HIV-exposed, uninfected infants.Association of HIV-1 Envelope-Specific Breast Milk IgA Responses with Reduced Risk of Postnatal Mother-to-Child Transmission of HIV-1Maternal or infant antiretroviral drugs to reduce HIV-1 transmissionCytomegalovirus IgG Level and Avidity in Breastfeeding Infants of HIV-Infected Mothers in Malawi.Prevalence of hepatitis C virus infection among human immunodeficiency virus-1-infected pregnant women in Malawi: the BAN studyMaternal and infant antiretroviral regimens to prevent postnatal HIV-1 transmission: 48-week follow-up of the BAN randomised controlled trial
P50
Q22241494-A262F051-A9AC-4389-8E21-4CCFA8ED462EQ23024073-71547468-7AB4-4D65-A2F8-3F350C5C25DCQ24261157-93019E4C-947D-4B66-B1E0-42AD2A08855BQ24261164-336F2858-9897-4F80-ADB2-477435973726Q24261270-49FD2907-8D08-4AA5-9C4E-3F26DB24B9B9Q24289620-1721DF1F-E819-4947-B1CD-5C7A8CC9342AQ26247045-769A9F5E-109C-4167-AF92-AD4CCC13D224Q26406299-40399DD6-8F41-4FFA-AD33-68400F87D486Q28005781-E70E240B-B5D3-477C-856B-3FC66CC0CA00Q28950428-D4A65554-5FA0-4A56-93B4-7FC3AFEBCAC6Q28956693-EDD5E3B2-7934-4C85-A72C-7C82F956A83CQ29168666-69206C5F-DAB5-4789-9433-A5DD33EB1AF7Q30151787-48130EB8-7306-46CC-8554-52B3FFE23B1DQ30401381-A323A7B9-B5ED-48B0-9516-AEA8CB5F5022Q30402099-EF62FAE5-E5F9-4AD1-AD07-2C2E47AAAE6DQ33763511-AE966C1D-CA87-4B3D-A1A0-799A2D859CE9Q33946645-DDD9681C-01B9-45B9-BD10-6A2B06CA1285Q33990216-F0D529F4-12C3-4167-B010-9E813C5531D1Q34371989-F00D9BEB-1383-43CF-8BFC-37A587CADBE6Q35003852-FEF26FF7-43FE-420A-B134-1B59644DAD24Q35163949-A60292C7-68E4-4680-B3C7-1A73B17A453AQ35286801-BF5139B2-9A16-4643-BF91-485F9DC981A9Q35297614-DC0FAA28-901D-48C1-BB29-C2F70AF5986BQ35399745-89DD371B-AF30-40C1-9426-DD2147417F65Q35423380-9E3B5976-B015-42BF-88F4-36BC7A9BE2E1Q35542406-E80C9DB9-5152-4597-BD91-E566F937128BQ35542419-ED328017-720E-4FAE-A32B-8D4CCE24C158Q35661129-3D2ECBE2-3440-4647-A63A-0C97C7338718Q35753149-36937DDF-58F5-4612-9E5B-15CD267CC460Q35825670-6DCE9317-CD60-4736-BCBA-9639B1C800E1Q35825690-400E14FE-248A-4C0A-A331-9A4055B21BD1Q35863995-1FBDE2D5-9B0B-41C8-800E-21732D883062Q35874984-898CF8C2-7DBC-4497-B429-4E38EBF1AE5EQ35926307-7CE57347-7B15-4EDD-85DC-D8E14C0CBB19Q35975609-E608DB9B-13B0-45E8-A703-70BF5DD2D6D7Q36080800-2C03F57A-32F5-4918-804D-7AA1583439A9Q36231035-7896312B-0155-4266-B756-336DC5ED4AADQ36316771-1DF274D2-695F-444C-B9C7-CC9785595F18Q36839535-A0383BB7-A4F0-4844-BEE8-442ABBE1CBA2Q36866309-BD4C93E9-B2F4-4FE4-AC6F-1B2D112D462E
P50
description
onderzoeker
@nl
name
Sascha R. Ellington
@ast
Sascha R. Ellington
@en
Sascha R. Ellington
@sl
type
label
Sascha R. Ellington
@ast
Sascha R. Ellington
@en
Sascha R. Ellington
@sl
prefLabel
Sascha R. Ellington
@ast
Sascha R. Ellington
@en
Sascha R. Ellington
@sl